Fact Sheet

The Cost of 340B to **New York**

In 2025, workers and employers lost $940 million in negotiated rebates to 340B

Despite advocates' claims that the 340B program is free, it raises costs for patients, employers, state and local governments, Medicare, and managed Medicaid. One way it increases costs is by displacing the negotiated rebates that are used to lower net drug prices. Research by IQVIA shows that workers and employers lost $14.5 billion in rebates nationally in 2025 due to 340B.[1] The cost to New York workers and employers in 2025 was $940 million.

Cost of 340B to New York workers and employers

PER BENEFICIARY	PLAN TYPE	TOTAL COST
$97	Private sector employees[2]	**$790M**
	Government employees[3]	**$150M**
	Total	**$940M**

The cost of 340B to New York has increased substantially in recent years due to program growth. From 2023 to 2025, the number of healthcare providers prescribing 340B drugs and the value of 340B drug purchases both increased while the number of 340B facilities fell slightly.

340B growth in New York: 2023 to 2025

340B PRESCRIBERS		340B FACILITIES[4]		340B DRUG PURCHASES[5]	
#	GROWTH	#	GROWTH	#	GROWTH
90,433	+28%	1,159	-3%	$14.9 billion	+62%

340B utilization varies markedly across New York and neighboring states, underscoring that the program's financial burden is not borne uniformly.

New York vs. neighbors

STATE	340B UTILIZATION[6]	COST PER BENEFICIARY
NY	17%	$97
MA	21%	$124
CT	20%	$114
NJ	4%	$25
Total U.S.	**14%**	**$81**

1. The cost of 340B to states. IQVIA. 2026 (to appear).
2. Includes employer-sponsored plans and ACA health plans.
3. Includes state and local government employees.
4. Based on 340B "parent" facilities, not satellite sites or contract pharmacies.
5. 340B drug purchases at Wholesaler Acquisition Cost (WAC).
6. Percentage of 340B business by state, averaged over drug purchases and claims.

CONTACT US

iqvia.com